Interpace Biopharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Interpace biopharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Interpace Biopharma Today - Breaking & Trending Today

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
March 17, 2021 07:30 ET
| Source:
Interpace Biosciences, Inc.
Interpace Biosciences, Inc.
Part of Company’s Site Consolidation and Cost Savings Measures
Parsippany, NJ, March 17, 2021 (GLOBE NEWSWIRE) Interpace Biosciences, Inc. (OTC: IDXG) announced today that it has entered into a definitive agreement to sell its New Haven CT CLIA certified, CAP accredited laboratory to DiamiR Biosciences, Corp. (DiamiR). This sale is in line with previously announced restructuring and cost reduction initiatives announced by Interpace. Under this agreement, DiamiR will provide overflow lab testing in support of the Company’s molecular thyroid testing products at its main laboratory in Pittsburgh, PA. DiamiR will also support specific Interpace assay development and validation services on behalf of the Company for the next three quarters. Subject to specific ter ....

Megan Paul , Interpace Bioscience , Interpace Biopharma , Tom Burnell , Interpace Biosciences Inc , Haven Laboratory , Securities Exchange , Part Of Company Site Consolidation , Edison Group , Site Consolidation , Cost Savings , New Haven , Diamir Biosciences , New Haven Laboratory , Interpace Biosciences , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Best Market , Annual Report , Current Reports , Quarterly Reports , Otc Markets Idxg , Otc Idxg , New Haven Clia Lab To Diamir , Cost Savings Measures ,

DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences

DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences
News provided by
Share this article
Share this article
MONMOUTH JUNCTION, N.J., March 17, 2021 /PRNewswire/ DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. Subject to specific terms and conditions of the agreement being met, it is anticipated that the transaction will close by the end of April, 2021. Financial terms of this transaction have not been disclosed. ....

Kira Sheinerman , Interpace Biosciences , Interpace Bioscience , Prnewswire Diami , Interpace Biopharma , Samuil Umansky , Interpace Biosciences Inc , Clinical Laboratory Improvement Amendments , New Haven , Chief Scientific Officer , மருத்துவ ஆய்வகம் முன்னேற்றம் திருத்தங்கள் , புதியது புகலிடம் , தலைமை அறிவியல் அதிகாரி ,

Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
Interpace Biosciences, Inc.February 1, 2021 GMT
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1, used in the risk assessment of pancreatic cysts. Although some cysts may have no cancerous potential at all, other cysts carry up to a 48 percent chance of harboring invasive cancer, and surgery to remove them is often complex. Therefore, there is a need to develop additional tools to identify which pancreatic cysts may develop into cancer and which ones will not. In a recent, national multicenter study of patients undergoing surgery for pancreatic cys ....

New Jersey , United States , Interpace Biosciences , Koushikk Das , Megan Paul , Interpace Bioscience , Interpace Biopharma , Tom Burnell , National Cancer Institute , Division Of Gastroenterology At Washington University , Edison Group , Interpace Biosciences Inc , Securities Exchange , University Of New Jersey , Pancreatic Cyst Biomarker Alliance , State University , Massachusetts General Hospital , Monoclonal Antibody , High Risk Mucinous Pancreatic Cystic , National Cancer , Washington University , Biopharma Business , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Annual Report ,